Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AXIS IIa: AX200 for Acute Ischemic Stroke
NCT00132470Phase 2Completed
- Sponsor
- Axaron Bioscience AG
- Start
- Dec 2004
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of filgrastim in ischemic stroke (5 arms), sponsored by Axaron Bioscience AG. Primary endpoint: Safety and Tolerability. Started Dec 2004; status: completed.
02
Drugs
filgrastim
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT00132470.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00132470.